<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03773887</url>
  </required_header>
  <id_info>
    <org_study_id>2014_30</org_study_id>
    <secondary_id>2014-A01452-45</secondary_id>
    <nct_id>NCT03773887</nct_id>
  </id_info>
  <brief_title>Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease</brief_title>
  <acronym>TargetOH</acronym>
  <official_title>Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is the comparison of the profile of the pro-inflammatory
      cytokines at the patients suffering from an alcoholic hepatitis to that of two groups
      witnesses: patients suffering from an alcoholic cirrhosis and unhurt patients of chronic
      liver disease
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the expression of proinflammatory cytokines</measure>
    <time_frame>Baseline</time_frame>
    <description>Proinflammatory Cytokines (TNF, IL-1, IL-6, IL-8)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the expression of genetic variants of pro-inflammatory cytokines</measure>
    <time_frame>Baseline</time_frame>
    <description>Identification of genetic variants of pro-inflammatory cytokines that contribute to mortality of Alcoholic Liver Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell lysis (AST, ALT, CK18 cleaved)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regeneration markers (Ki-67, Fn14, CK7)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Liver Diseases</condition>
  <condition>Acute on Chronic Hepatic Failure</condition>
  <arm_group>
    <arm_group_label>acute alcoholic hepatitis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>collection of liver biopsies collection of blood samples in patients with acute alcoholic hepatitis (group A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcoholic cirrhosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>collection of liver biopsies collection of blood samples in patients with alcoholic cirrhosis (group B1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without chronic liver disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>collection of liver biopsies collection of blood samples in patients without chronic liver disease (group B2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>collection of liver biopsies collection of blood samples</intervention_name>
    <description>blood and ascites samples; extraction of explants, hepatic resection parts; hepatic parenchyma on liver biopsies</description>
    <arm_group_label>Alcoholic cirrhosis</arm_group_label>
    <arm_group_label>Without chronic liver disease</arm_group_label>
    <arm_group_label>acute alcoholic hepatitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  group A: patients with acute alcoholic hepatitis

          -  Active alcohol abuse defined by DSM IV and excessive alcohol consumption prior to
             admission (&gt; 60 g per day for men and&gt; 40 g per day for women)

          -  Moderate elevation of transaminases (less than 500 U / L) with a typical ASAT / ALAT
             ratio of 2: 1

          -  Bilirubin&gt; 50 mg / l

          -  Absence of autoimmune liver disease (ANA &lt;1/80, AML &lt;1/80, LKM1 neg, AAM neg)

          -  Absence of hepatitis B and C and HIV infection (negative anti-HIV antibodies, negative
             HBsAg, negative HCV PCR)

          -  Patients with other acute complications than alcoholic hepatitis may be included (eg,
             digestive hemorrhage, acute renal failure, infection, etc.)

          -  Because there is no validated noninvasive tool for the diagnosis of alcoholic
             hepatitis, histological confirmation is required in all patients (preferably by
             transjugular biopsy): alcoholic hepatitis will be diagnosed on the presence of the
             following histological characteristics: Hepatocellular lesions (ballooning, Mallory
             body)/ Inflammatory infiltrate with polymorphonuclear neutrophils

          -  group B1: patients with alcoholic cirrhosis

          -  Decompensated or non-decompensated alcoholic cirrhosis, defined according to the HAS
             guidelines, ie by a liver biopsy or a cluster of clinico-biological arguments
             (www.has-sante.fr)

          -  group B2: patients free from chronic liver disease

          -  Justification of blood and liver sampling for the management of a pathology other than
             chronic liver disease (eg liver metastasis of digestive cancer occurring on healthy
             liver)

        Exclusion Criteria:

          -  For groups A and B1:

          -  Patients with hepatocellular carcinoma of progressive non-hepatic cancer

          -  Presence of HBsAg

          -  Presence of anti-HCV antibodies by positive PCR

          -  Presence of antibodies to HIV 1 +2

          -  Pregnancy

          -  for group B2:

          -  Alcoholic liver disease

          -  Presence of HBsAg

          -  Presence of anti-HCV antibodies by positive PCR

          -  Presence of antibodies to HIV 1 +2

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philppe Mathurin, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Mathurin, MD,PhD</last_name>
    <phone>03 20 44 55 97</phone>
    <phone_ext>+33</phone_ext>
    <email>philippe.mathurin@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>HÃ´pital Claude Huriez, CHRU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Mathruin, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Louvet, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 16, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>December 11, 2018</last_update_submitted>
  <last_update_submitted_qc>December 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

